文献速递卫生政策与健康促进免疫规划

中国疫苗产品说明书公开可及性与完整性研究

Public availability and completeness of vaccine product labeling in China.
PubMed 文献 · Vaccine · 2026-09-29

该横断面研究评估国家药品监督管理局批准的309种疫苗说明书的公开可及性与完整性,发现163种(52.8%)可公开获取,175种市场活跃疫苗中151种(86.3%)可获取,完整性中位评分为0.89,临床相关章节存在明显缺陷。

要点

  • 309种获批疫苗中仅52.8%说明书可公开获取,市场活跃疫苗可获取率为86.3%。
  • 说明书完整性中位评分0.89,药物相互作用、特殊人群和临床试验章节缺陷最明显。
  • 进口疫苗及2022年5月20日后修订的说明书完整性评分更高。

核心结论

  • 中国疫苗说明书在公开可及性和临床相关信息完整性方面仍存在差距,需加强及时披露与更新。

研究设计与样本

  • 横断面研究,纳入国家药品监督管理局批准的全部309种疫苗,评估其公开说明书可及性与完整性。

主要发现

  • 309种获批疫苗中163种(52.8%)说明书可公开获取,175种市场活跃疫苗中151种(86.3%)可获取。
  • 完整性中位评分为0.89(四分位距0.83-0.93)。
  • 药物相互作用、特殊人群和临床试验等临床相关章节缺陷最明显。
  • 进口疫苗完整性评分高于国产疫苗,2022年5月20日及以后修订的说明书评分高于此前修订者。

关键数值与推荐

  • 完整性评估采用基于国家药监局监管指南的26项预设框架,完整性评分为适用条目平均分。
  • 市场活跃疫苗定义为近3年内至少有一批次放行记录的疫苗。

临床怎么用

  • 临床决策时应关注疫苗说明书是否公开可及及其临床相关章节的完整性。
  • 对国产疫苗及2022年5月20日前修订的说明书,需谨慎核查药物相互作用与特殊人群信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Publicly accessible vaccine package inserts are essential for regulatory transparency and informed clinical decision-making. However, the public availability and completeness of vaccine labeling in China remain unclear. We conducted a cross-sectional study of all vaccines approved by the National Medical Products Administration (NMPA) to evaluate the availability and completeness of publicly accessible package inserts, including both domestic and imported vaccines. Package inserts were retrieved from the NMPA vaccine labeling database as of 22 August 2026. Vaccines with at least one lot-release record during the preceding 3 years were classified as market-active. Labeling completeness was assessed using a predefined framework comprising 26 items derived from NMPA regulatory guidance. Completeness scores were calculated as the mean applicable item score. Among 309 unique approved vaccines, package inserts were publicly available for 163 (52.8%) vaccines and for 151 of 175 (86.3%) currently marketed vaccines. The median completeness score was 0.89 (interquartile range, 0.83-0.93). Deficiencies were most pronounced in clinically relevant sections, including drug interactions, special populations, and clinical trials. Completeness scores were higher for imported than domestic vaccines and for package inserts last revised on or after 20 May 2022 than for those revised before that date. Despite recent regulatory efforts to improve transparency gaps remain in public availability and the completeness of clinically relevant information in vaccine package inserts in China. Strengthening the timely disclosure and updating of vaccine labeling may improve regulatory transparency and support informed vaccination decisions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ding Y, Fu M, Ramachandran R, et al. Public availability and completeness of vaccine product labeling in China. Vaccine. 2026. PMID: 42810175. doi:10.1016/j.vaccine.2026.129185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。